2026-10-30 00:40:51 UTC#541992updateconfirmednews
BBIO stock news
BBIO stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-29 23:44:41 UTC#541792duplicateconfirmednews
BridgeBio Pharma Q3 revenue $353.2M, Attruby sales up 134% YoY
2026-10-29 21:01:00 UTC#540915duplicateconfirmeddata release
BridgeBio Pharma Q3 2026 Revenue $353.17M, Net Loss $83M, EPS ($0.42)
2026-10-29 20:14:37 UTC#540635updateconfirmednews
BridgeBio Pharma Q3 revenue doubles on Attruby sales and Bayer milestone; updates pipeline launch timelines
2026-10-29 20:01:00 UTC#540300duplicateconfirmednews
BridgeBio Pharma reports Q3 2026 loss of $0.42 per share
2026-10-29 20:01:00 UTC#540297newconfirmeddata release
BridgeBio Pharma reports Q3 2026 net loss of $60.5 million
2026-10-20 18:23:00 UTC#488293newconfirmednews
Oppenheimer maintains BridgeBio Pharma at Outperform, cuts price target to $16 from $22
2026-10-19 20:59:00 UTC#483149newconfirmednews
Citigroup maintains Neutral rating on BridgeBio Pharma, cuts price target to $91 from $94
2026-10-19 16:31:00 UTC#481850newconfirmednews
Piper Sandler maintains Overweight rating on BridgeBio Pharma
2026-10-15 21:50:00 UTC#468658newconfirmednews
UBS assumes coverage of BridgeBio Pharma (BBIO) with Buy rating
2026-10-13 10:03:00 UTC#451191newconfirmednews
BridgeBio's Infigratinib for Achondroplasia Granted FDA Priority Review; PDUFA Date Set for Feb 4, 2027
tradingviewimportance 0.60trust 0.80BridgeBio Pharma, Inc. +0.60Food and Drug Administration +0.50Infigratinib +0.60+1 entities
2026-10-11 18:30:00 UTC#443667newconfirmednews
BridgeBio's Acoramidis Shows 18% Lower Risk of Composite Clinical Outcomes vs Tafamidis in Real-World ATTR-CM Study
globenewswireimportance 0.50trust 0.70BridgeBio Pharma, Inc. +0.60Pfizer Inc. -0.40Epic Systems Corporation 0+1 entities
2026-10-11 16:09:22 UTC#443476newconfirmednews
BridgeBio Pharma reports positive Phase 3 trial results for rare-disease drug candidate
2026-10-07 13:42:00 UTC#426066newconfirmednews
Barclays maintains Overweight rating on BridgeBio Pharma (BBIO)
2026-10-06 11:30:00 UTC#419013newconfirmednews
BridgeBio Pharma's Infigratinib for Achondroplasia Granted FDA Priority Review; PDUFA Set for Feb 4, 2027
tradingviewimportance 0.60trust 0.80BridgeBio Pharma, Inc. +0.60Infigratinib +0.60Food and Drug Administration +0.50
2026-10-06 11:30:00 UTC#419007newconfirmedpress release
BridgeBio's Infigratinib for Achondroplasia Granted FDA Priority Review with Feb 4, 2027 PDUFA Date
globenewswireimportance 0.70trust 0.90BridgeBio Pharma, Inc. +0.60Food and Drug Administration +0.50Infigratinib +0.60+2 entities
2026-10-05 11:40:24 UTC#413035newconfirmednews
BridgeBio Pharma BBP-418 meets all endpoints in Phase 3 FORTIFY trial, normalizing cardiac markers
reutersimportance 0.70trust 0.90BridgeBio Pharma, Inc. +0.80BBP-418 +0.80Food and Drug Administration +0.50+1 entities
2026-09-23 14:43:48 UTC#356381newconfirmednews
BridgeBio Pharma's Attruby surpasses $1B in annualized sales; three new product launches expected within a year
2026-09-23 12:25:16 UTC#355327newreportednews
BridgeBio's Attruby outperforms Pfizer's Vyndamax in real-world heart disease study, Seeking Alpha reports
seeking alphaimportance 0.60trust 0.60BridgeBio Pharma, Inc. +0.60Pfizer Inc. -0.40Attruby +0.60+1 entities
2026-09-16 15:30:17 UTC#321784newconfirmednews